Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Al Razi Medical CoSAU:9572 +1.95%49 Return-on-Tangible-Equity is 3.56% as of Jun. 2026, which is 8% above its 10-year median of 3.31. GuruFocus rates SAU:9572 with a GF Score™ of 49/100 and a GF Value™ of ﷼56.92 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 578 Healthcare Providers & Services companies, Al Razi Medical Co ranks worse than 65.4% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Al Razi Medical Co's annualized net income for the quarter that ended in Jun. 2026 was ﷼0.84 Mil. Al Razi Medical Co's average shareholder tangible equity for the quarter that ended in Jun. 2026 was ﷼23.54 Mil. Therefore, Al Razi Medical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 3.56%.
The historical rank and industry rank for Al Razi Medical Co's Return-on-Tangible-Equity or its related term are showing as below:
SAU:9572'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.8 Med: 3.31 Max: 8.63
Current: 4.87
During the past 4 years, Al Razi Medical Co's highest Return-on-Tangible-Equity was 8.63%. The lowest was 0.80%. And the median was 3.31%.
SAU:9572's Return-on-Tangible-Equity is ranked worse than 65.4% of 578
companies
in the Healthcare Providers & Services industry
Industry Median: 10.7
vs SAU:9572: 4.87
Al Razi Medical Co (SAU:9572) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Al Razi Medical Co Return-on-Tangible-Equity Related Terms
Al Razi Medical Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Al Razi Medical Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Al Razi Medical Co Return-on-Tangible-Equity Chart
Al Razi Medical Co Return-on-Tangible-Equity Competitor Comparison
For the Pharmaceutical Retailers subindustry, Al Razi Medical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Al Razi Medical Co Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Al Razi Medical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Al Razi Medical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 3.56% mean?
Al Razi Medical Co (SAU:9572) has a Return-on-Tangible-Equity of 3.56% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Al Razi Medical Co and its competitors. This is near median its historical median of 3.31. Over the past decade, Al Razi Medical Co's Return-on-Tangible-Equity has ranged from 0.80 to 8.63. According to the industry distribution chart, Al Razi Medical Co ranks #378 out of 578 companies in the Healthcare Providers & Services industry, placing it in the top 65.4%.
Is Al Razi Medical Co's Return-on-Tangible-Equity too high?
Al Razi Medical Co's current Return-on-Tangible-Equity of 3.56% is near median its 10-year median of 3.31. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 8.63. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.70. Al Razi Medical Co's value of 3.56% is 66.7% below this industry median. Based on the distribution chart, Al Razi Medical Co ranks #378 out of 578 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Al Razi Medical Co has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Al Razi Medical Co's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Al Razi Medical Co ranks #378 out of 578 companies for Return-on-Tangible-Equity. This places Al Razi Medical Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.70. Al Razi Medical Co's value of 3.56% is 66.7% below this benchmark. Historically, Al Razi Medical Co's own Return-on-Tangible-Equity has ranged from 0.80 to 8.63 over the past decade. While the company's 10-year median is 3.31 vs. the industry median of 10.70, Al Razi Medical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.70, based on 578 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Al Razi Medical Co's current Return-on-Tangible-Equity of 3.56% is 66.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Al Razi Medical Co and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Al Razi Medical Co's current Return-on-Tangible-Equity is 3.56%, which is near median its own 10-year median of 3.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Al Razi Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Al Razi Medical Co (SAU:9572) is currently considered Significantly Undervalued. The stock's GF Value™ is ﷼56.92, compared to a current price of ﷼27.22 — trading 52.2% below its estimated fair value. The current Return-on-Tangible-Equity is 3.56%, which is near median its 10-year median of 3.31 and 66.7% below the Healthcare Providers & Services industry median of 10.70. Al Razi Medical Co's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Al Razi Medical Co (SAU:9572), the current Return-on-Tangible-Equity is 3.56% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Al Razi Medical Co (SAU:9572) Overvalued in 2026?
Based on GuruFocus' analysis, Al Razi Medical Co stock appears to be undervalued.
The current stock price of ﷼27.22 is trading 52.2% below its estimated GF Value™ of ﷼56.92.
GuruFocus considers Al Razi Medical Co to be Significantly Undervalued.
Key valuation signals for SAU:9572:
Return-on-Tangible-Equity: 3.56% (near median its 10-year median of 3.31)
GF Value™: ﷼56.92 vs. price of ﷼27.22 (52.2% below fair value)
Industry Position: 66.7% below the Healthcare Providers & Services median (#378 of 578)
No single metric tells the full story. See the SAU:9572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Al Razi Medical Co operates in the medical field in the Kingdom of Saudi Arabia. The company provides all pharmaceutical and cosmetic products. It engages in buying and selling pharmaceuticals, medical supplies, herbal and cosmetic products, and all related products on a wholesale and retail basis.
49GF Score
Get the complete analysis for SAU:9572
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:9572 has been successfully added to your 
